A phase I pharmacokinetic and translational study of the novel vascular targeting agent combretastatin A-4 phosphate on a single-dose intravenous schedule in patients with advanced cancer

Afshin Dowlati, Kelly Robertson, Matthew Cooney, William P. Petros, Michael Stratford, John Jesberger, Niusha Rafie, Beth Overmoyer, Vinit Makkar, Bruce Stambler, Anne Taylor, John Waas, Jonathan S. Lewin, Keith R. McCrae, Scot C. Remick

Research output: Contribution to journalArticle

Abstract

Combretastatin A-4 phosphate (CA4P) is a novel antitumor vascular targeting agent, the first agent of this class of compounds to enter the clinic. We performed a Phase I trial to determine the maximum-tolerated dose, safety, and pharmacokinetic profile of CA4P on a single-dose i.v. schedule. We also obtained preliminary data on its effect on tumor blood flow using dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI) techniques and cell adhesion molecules at the higher-dose levels. Twenty-five assessable patients with advanced cancer received a total of 107 cycles over the following dose escalation schema: 18, 36, 60, 90 mg/m2 as a 10-min infusion and 60 mg/m2 as a 60-min infusion at 3-week intervals. There was no significant myelotoxicity, stomatitis, or alopecia. Tumor pain was a unique side effect, which occurred in 10% of cycles, and there were four episodes of dose-limiting toxicity at dosages ≥60 mg/m2, including two episodes of acute coronary syndrome. Pharmacokinetics revealed rapid dephosphorylation of the parent compound (CA4P) to combretastatin A4 (CA4), with a short plasma half-life (30 min). A significant (P <0.03) decline in gradient peak tumor blood flow by DCE-MRI in six of seven patients treated at 60 mg/m2 was observed. A patient with anaplastic thyroid cancer had a complete response and is alive 30 months after treatment. The toxicity profile is consistent with a drug that is "vascularly active" and devoid of traditional "cytotoxic" side effects. Dosages ≤60 mg/m2 as a 10-min infusion define the upper boundary of the maximum-tolerated dose.

Original languageEnglish (US)
Pages (from-to)3408-3416
Number of pages9
JournalCancer Research
Volume62
Issue number12
StatePublished - Jun 15 2002
Externally publishedYes

Fingerprint

Blood Vessels
Appointments and Schedules
Pharmacokinetics
Phosphates
Maximum Tolerated Dose
Neoplasms
Magnetic Resonance Imaging
Stomatitis
Alopecia
Cell Adhesion Molecules
Acute Coronary Syndrome
Half-Life
Safety
Pain
fosbretabulin
Pharmaceutical Preparations
Therapeutics

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

A phase I pharmacokinetic and translational study of the novel vascular targeting agent combretastatin A-4 phosphate on a single-dose intravenous schedule in patients with advanced cancer. / Dowlati, Afshin; Robertson, Kelly; Cooney, Matthew; Petros, William P.; Stratford, Michael; Jesberger, John; Rafie, Niusha; Overmoyer, Beth; Makkar, Vinit; Stambler, Bruce; Taylor, Anne; Waas, John; Lewin, Jonathan S.; McCrae, Keith R.; Remick, Scot C.

In: Cancer Research, Vol. 62, No. 12, 15.06.2002, p. 3408-3416.

Research output: Contribution to journalArticle

Dowlati, A, Robertson, K, Cooney, M, Petros, WP, Stratford, M, Jesberger, J, Rafie, N, Overmoyer, B, Makkar, V, Stambler, B, Taylor, A, Waas, J, Lewin, JS, McCrae, KR & Remick, SC 2002, 'A phase I pharmacokinetic and translational study of the novel vascular targeting agent combretastatin A-4 phosphate on a single-dose intravenous schedule in patients with advanced cancer', Cancer Research, vol. 62, no. 12, pp. 3408-3416.
Dowlati, Afshin ; Robertson, Kelly ; Cooney, Matthew ; Petros, William P. ; Stratford, Michael ; Jesberger, John ; Rafie, Niusha ; Overmoyer, Beth ; Makkar, Vinit ; Stambler, Bruce ; Taylor, Anne ; Waas, John ; Lewin, Jonathan S. ; McCrae, Keith R. ; Remick, Scot C. / A phase I pharmacokinetic and translational study of the novel vascular targeting agent combretastatin A-4 phosphate on a single-dose intravenous schedule in patients with advanced cancer. In: Cancer Research. 2002 ; Vol. 62, No. 12. pp. 3408-3416.
@article{1f036357cbaa47f7b5040cace6633bbb,
title = "A phase I pharmacokinetic and translational study of the novel vascular targeting agent combretastatin A-4 phosphate on a single-dose intravenous schedule in patients with advanced cancer",
abstract = "Combretastatin A-4 phosphate (CA4P) is a novel antitumor vascular targeting agent, the first agent of this class of compounds to enter the clinic. We performed a Phase I trial to determine the maximum-tolerated dose, safety, and pharmacokinetic profile of CA4P on a single-dose i.v. schedule. We also obtained preliminary data on its effect on tumor blood flow using dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI) techniques and cell adhesion molecules at the higher-dose levels. Twenty-five assessable patients with advanced cancer received a total of 107 cycles over the following dose escalation schema: 18, 36, 60, 90 mg/m2 as a 10-min infusion and 60 mg/m2 as a 60-min infusion at 3-week intervals. There was no significant myelotoxicity, stomatitis, or alopecia. Tumor pain was a unique side effect, which occurred in 10{\%} of cycles, and there were four episodes of dose-limiting toxicity at dosages ≥60 mg/m2, including two episodes of acute coronary syndrome. Pharmacokinetics revealed rapid dephosphorylation of the parent compound (CA4P) to combretastatin A4 (CA4), with a short plasma half-life (30 min). A significant (P <0.03) decline in gradient peak tumor blood flow by DCE-MRI in six of seven patients treated at 60 mg/m2 was observed. A patient with anaplastic thyroid cancer had a complete response and is alive 30 months after treatment. The toxicity profile is consistent with a drug that is {"}vascularly active{"} and devoid of traditional {"}cytotoxic{"} side effects. Dosages ≤60 mg/m2 as a 10-min infusion define the upper boundary of the maximum-tolerated dose.",
author = "Afshin Dowlati and Kelly Robertson and Matthew Cooney and Petros, {William P.} and Michael Stratford and John Jesberger and Niusha Rafie and Beth Overmoyer and Vinit Makkar and Bruce Stambler and Anne Taylor and John Waas and Lewin, {Jonathan S.} and McCrae, {Keith R.} and Remick, {Scot C.}",
year = "2002",
month = "6",
day = "15",
language = "English (US)",
volume = "62",
pages = "3408--3416",
journal = "Journal of Cancer Research",
issn = "0099-7013",
publisher = "American Association for Cancer Research Inc.",
number = "12",

}

TY - JOUR

T1 - A phase I pharmacokinetic and translational study of the novel vascular targeting agent combretastatin A-4 phosphate on a single-dose intravenous schedule in patients with advanced cancer

AU - Dowlati, Afshin

AU - Robertson, Kelly

AU - Cooney, Matthew

AU - Petros, William P.

AU - Stratford, Michael

AU - Jesberger, John

AU - Rafie, Niusha

AU - Overmoyer, Beth

AU - Makkar, Vinit

AU - Stambler, Bruce

AU - Taylor, Anne

AU - Waas, John

AU - Lewin, Jonathan S.

AU - McCrae, Keith R.

AU - Remick, Scot C.

PY - 2002/6/15

Y1 - 2002/6/15

N2 - Combretastatin A-4 phosphate (CA4P) is a novel antitumor vascular targeting agent, the first agent of this class of compounds to enter the clinic. We performed a Phase I trial to determine the maximum-tolerated dose, safety, and pharmacokinetic profile of CA4P on a single-dose i.v. schedule. We also obtained preliminary data on its effect on tumor blood flow using dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI) techniques and cell adhesion molecules at the higher-dose levels. Twenty-five assessable patients with advanced cancer received a total of 107 cycles over the following dose escalation schema: 18, 36, 60, 90 mg/m2 as a 10-min infusion and 60 mg/m2 as a 60-min infusion at 3-week intervals. There was no significant myelotoxicity, stomatitis, or alopecia. Tumor pain was a unique side effect, which occurred in 10% of cycles, and there were four episodes of dose-limiting toxicity at dosages ≥60 mg/m2, including two episodes of acute coronary syndrome. Pharmacokinetics revealed rapid dephosphorylation of the parent compound (CA4P) to combretastatin A4 (CA4), with a short plasma half-life (30 min). A significant (P <0.03) decline in gradient peak tumor blood flow by DCE-MRI in six of seven patients treated at 60 mg/m2 was observed. A patient with anaplastic thyroid cancer had a complete response and is alive 30 months after treatment. The toxicity profile is consistent with a drug that is "vascularly active" and devoid of traditional "cytotoxic" side effects. Dosages ≤60 mg/m2 as a 10-min infusion define the upper boundary of the maximum-tolerated dose.

AB - Combretastatin A-4 phosphate (CA4P) is a novel antitumor vascular targeting agent, the first agent of this class of compounds to enter the clinic. We performed a Phase I trial to determine the maximum-tolerated dose, safety, and pharmacokinetic profile of CA4P on a single-dose i.v. schedule. We also obtained preliminary data on its effect on tumor blood flow using dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI) techniques and cell adhesion molecules at the higher-dose levels. Twenty-five assessable patients with advanced cancer received a total of 107 cycles over the following dose escalation schema: 18, 36, 60, 90 mg/m2 as a 10-min infusion and 60 mg/m2 as a 60-min infusion at 3-week intervals. There was no significant myelotoxicity, stomatitis, or alopecia. Tumor pain was a unique side effect, which occurred in 10% of cycles, and there were four episodes of dose-limiting toxicity at dosages ≥60 mg/m2, including two episodes of acute coronary syndrome. Pharmacokinetics revealed rapid dephosphorylation of the parent compound (CA4P) to combretastatin A4 (CA4), with a short plasma half-life (30 min). A significant (P <0.03) decline in gradient peak tumor blood flow by DCE-MRI in six of seven patients treated at 60 mg/m2 was observed. A patient with anaplastic thyroid cancer had a complete response and is alive 30 months after treatment. The toxicity profile is consistent with a drug that is "vascularly active" and devoid of traditional "cytotoxic" side effects. Dosages ≤60 mg/m2 as a 10-min infusion define the upper boundary of the maximum-tolerated dose.

UR - http://www.scopus.com/inward/record.url?scp=0037096814&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0037096814&partnerID=8YFLogxK

M3 - Article

C2 - 12067983

AN - SCOPUS:0037096814

VL - 62

SP - 3408

EP - 3416

JO - Journal of Cancer Research

JF - Journal of Cancer Research

SN - 0099-7013

IS - 12

ER -